Solid Tumor

Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial

Adagene's Posts Early Safety, Efficacy Data From Cold Tumors Trial

Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients

Adagene's Posts Early Safety, Efficacy Data From Cold Tumors Trial

Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients

SQZ Biotechnologies' Cell Therapy Shows Favorable Safety Profile In HPV+ Solid Tumors

Mereo BioPharma's Etigilimab/Opdivo Combo Achieves One Complete Response In Cervical Cancer

SQZ Biotechnologies' Cell Therapy Shows Favorable Safety Profile In HPV+ Solid Tumors

Mereo BioPharma's Etigilimab/Opdivo Combo Achieves One Complete Response In Cervical Cancer

Adagene Shares Jump After FDA Signs Off ADG116/Keytruda Combo Therapy Trial In Solid Tumors

Codiak BioSciences' Exosome Candidate Shows Tumor Shrinkage In Early Study

Solid Tumor Recent News

Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers

Moderna Posts Interim Data From mRNA Triplet Program In Solid Tumors

Why Did Oncorus Shares Slump To 52-Week Low Today?

Oncorus Inc (NASDAQ: ONCR) shares slumped after the company reported initial data for its investigational cancer therapy ONCR-177 from a Phase 1 trial in heavily pretreated patients with advanced, injectable solid tumors.

Agenus Posts Early Data For CTLA-4 Drug Candidate Across Tumor Types

Takeda, Shattuck Labs Terminate Immuno-Oncology Pact

Shattuck Labs Inc (NASDAQ: STTK) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) mutually agreed to terminate the Collaboration Agreement for SL-279252 and SL-115154.

ALX Oncology Falls After Updated Data For Solid Tumors Candidate

Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor Setting

Turning Point Reveals Early Repotrectinib Data In NTRK+ Advanced Solid Tumors

Turning Point Therapeutics Inc (NASDAQ: TPTX) announced early data from TRIDENT-1 Phase 1/2 study of its lead drug candidate repotrectinib.

Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial

Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?

Amgen Highlights Lumakras Combination Data From Solid Tumor Trials

Why Are Merus Shares Soaring Thursday?

GeoVax Stock Is Trading Higher On Gedeptin In-Licensing Pact For Solid Tumors

Why Are I-Mab Shares Trading Higher On Tuesday?

Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO

Aprea Therapeutics Inc (NASDAQ: APRE) presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase 1/2 trial in advanced solid tumors. The trial is evaluating the safety and efficacy of eprenetapopt in combination with pembrolizumab.

Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings

TCR2 Therapeutics Stock Plunges On Safety Signals From Gavo-cel Solid Tumor Trial

TCR2 Therapeutics Inc (NASDAQ: TCRR) stock dropped to a 52-week low after interim results from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors.

NGM Bio Presents Preliminary Data From NGM120 Solid Tumor Trial

Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial

Silverback Therapeutics Presents Initial Safety Data From Solid Tumor Combo Therapy Trial

Adaptimmune Shares Encouraging Data From Solid Tumor Trial

Werewolf Therapeutics Inks Solid Tumor Trial Collaboration With Merck

Werewolf Therapeutics Inc (NASDAQ: HOWL) has entered into a

AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication